Olympus and the FDA: Expert Call with a Former FDA Director

研报英文原文证据摘录

Olympus and the FDA: Expert Call with a Former FDA Director

Insights with Experts

June 26, 2026

Expert

SeriesJapan | Medical Supplies & Devices

EXPERT STUDIESOlympus and the FDA: Expert Call with a

Former FDA Director GUEST SPEAKER

We hosted Former FDA Director Ricki Chase to discuss Olympus. Ricki Ricki Chase

considers Olympus' long-running issues with the FDA a result of the firm's President and Owner of RChase

Consultingculture. This aligns with the premise of our recent upgrade (report), which

identifies recent leadership changes as the first and most crucial step HOSTED BY

on Olympus' path to rehabilitation. Please see below for a lightly edited Stephen Barker

transcript of our call, and a link to the video. Head of Japan Healthcare Research

FDA issues overhang the stock. In our view, Olympus' unresolved issues with the FDA

represent an overhang that is deterring investors from buying its shares. However, we consider

recent leadership changes as a crucial first step in transforming Olympus' culture in a way

that will enable it to solve its issues with the FDA. Therefore, we recently upgrade the shares

to Buy (report). Timing, however, remains uncertain. Therefore, in order to better understand .

the scope of Olympus' regulatory challenges, the potential paths to resolution, and the time

required, we hosted former FDA Director Ricki Chase for a focused discussion on the history, Watch the Video:

current status of, and potential paths to resolving Olympus' problems with the FDA.

Directly involved with Olympus inspections. Ricki Chase is very familiar with Olympus’s

history because she was directly involved with the investigations surrounding the firm's

"superbug" contamination issues (2009-2015). And also because since leaving the agency 10